TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01708928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT02457728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBandFix8
Description: Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
Study: NCT01247688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/m2/day will be given IV over 1 hour on day -4, -3, -2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 1.75Gy/fraction will be given on day -9, -8, -7, -6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Blood Stem Cell Infusion
Description: The cord blood stem cells will be infused on day 0
Study: NCT03700710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Approach
Description: For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian-led Approach
Description: For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information.~From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform.~In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.~Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis.
Study: NCT03120585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Management Intervention
Description: Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR \>4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
Study: NCT04147728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
Study: NCT00613847

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
Description: Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab
Description: Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
Study: NCT02189876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FemAALES
Description: Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
Study: NCT04368052

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mini Mental Test (MMT), S-100 beta, Neuron specific enolase and Glial fibrillary acidic protein
Description: Patients undergoing liver transplantation (LTx) were measured using the Mini Mental Test (MMT) whereas simultaneous neuronal damage was evaluated through the measurement of S-100 beta (S100β), Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP) levels.
Study: NCT01567774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: os, 10 mg, once per day, for 30 days
Study: NCT03147690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
Study: NCT02029066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-T100 gel
Description: 2g of SR-T100 will topical apply on 100 cm\^2 once for 24 hours.
Study: NCT01664663

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiochemotherapy to 68 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalated radiochemotherapy up to 84 Gy
Study: NCT04275011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance and Impact Exercise
Description: Full body resistance and impact exercises will be performed twice a week for 30-45 minutes over a 6 month period. There will be at least one day of rest between scheduled exercise sessions. Participants will be individually prescribed variations of push, pull, squat, lift and carry movements targeting major muscle groups that they can safely complete, and accessory exercises to help develop movement patterns. Exercises will challenge both the upper and lower body using functional movement patterns. Each muscle group will be trained twice a week. During the first month, participants will focus on completing exercises with good form at a low intensity. Once form is mastered, exercises will be progressed (by increasing load, or challenge of the movement) to a moderate to high exercise intensity (80-85% 1RM) so that the participant can complete a maximum of 8 (\~80% 1RM) or 6 (\~85% 1RM) repetitions with 1-2 repetitions in reserve for 3 sets at a rating of perceived exertion (RPE) of 8-9.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Balance and Postural Exercise
Description: Participants in the attention control group will perform static posture and balance exercises (e.g., low intensity yoga poses) and will be given the same attention as the participants in the intervention group. The small group exercises will be performed twice a week, 30-45 minutes per session, over 6 months, with at least one day of rest between each session. The exercise program will be supervised by a certified personal trainer and yoga instructor who is BoneFit trained.
Study: NCT01076673

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells and hyaluronic acid injections
Description: Peripheral blood stem cells and hyaluronic acid injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid injections
Study: NCT01703572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-52M51
Study: NCT04194463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChemoFit exercise prehabilitation intervention
Description: Exercise intervention consists of walking monitored by wearing a pedometer device. After a baseline measurement of participant's walking activity is done, increase in step count from baseline step count is prescribed. This increase in step count is achieved by walking or jogging at moderate intensity for a target of 30 minutes per day, each day. Participants are also encouraged to perform other physical if they wish and are able to. Patients are regularly contacted by a member of the research team on a weekly basis and given an option to maintain or to increase their step count further. The same approach is used after each week of the intervention. Strengthening exercises will form a further part of the exercise intervention. They are performed every day, 7 days a week. Patients are supplied with resistance bands with handles. They are educated on how to perform two repetitions of 5 simple exercises, each for 1 minute duration.
Study: NCT00618592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PreOp carbohydrate drink
Description: 800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
Study: NCT01757535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: 300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Study: NCT01508611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30% silver diammine fluoride
Description: The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene
Description: With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
Study: NCT02772926

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine
Description: Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 900 mg per day
Study: NCT01473823

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 LCPUFA
Description: Dosage is 5 ml daily until age 3 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 LCPUFA
Description: Dosage is 5 ml daily until age 3 years.
Study: NCT00556946

Intervention type: DRUG
Group type: OTHER
Intervention: Combined Photodynamic & Pulsed Dye Laser Treatment
Description: Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
Study: NCT02321657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad app containing art, music and games
Description: An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toys, books and games
Description: Games, books and toys used to distract
Study: NCT02283424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy (Carboplatin and Docetaxel)
Description: as control group,compared with Icotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Carboplatin and Docetaxel)
Description: as control group,compared with Icotinib
Study: NCT01537601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumcision
Description: Circumcision

Intervention type: OTHER
Group type: OTHER
Intervention: Antibiotic prophylaxis alone
Description: Antibiotic prophylaxis alone
Study: NCT00598741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Description: Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner.
Study: NCT00730483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVA microporous hydrospheres/doxorubicin hydrochloride
Study: NCT03801369

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO (orally)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV (infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO (orally)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO (orally)
Study: NCT02597504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pen and paper neuropsychological test
Description: Will be administered for Construct Validity to determine agreement with Quick Test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quick Test
Description: Quick Test, computerized test will be administered to all subjects.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quick Test
Description: Quick Test, computerized test will be administered to all subjects.
Study: NCT03187301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: APL-130277 single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study: NCT02300376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosage of Calcium edetate de sodium
Description: There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
Study: NCT04292574

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their conditions.
Study: NCT04330300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazide or Thiazide-like diuretics
Description: Anti-hypertensive (Active Arm)
Study: NCT03187301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: moxifloxacin 400mg single dose
Study: NCT02647957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Code Stroke
Description: Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
Study: NCT03390751

Intervention type: OTHER
Intervention: Data collection
Description: The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
Study: NCT02498704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Trigger point dry needling to hamstring muscle group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: Superficial palpation of trigger point, skin is not punctured.
Study: NCT02992041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injections
Description: IV infusion of 900 or 1100 mg of VVZ-149
Study: NCT04330300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers
Description: Anti-hypertensive (Active Arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Anti-hypertensive (Control Arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blocker
Description: Anti-hypertensive (Control Arm)
Study: NCT04450290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CIDEXEL implant
Description: The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
Study: NCT01718054

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vascular ready-to-use supplementary food
Description: Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Ready-to-use supplementary food
Description: Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study: NCT02902731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: subcutaneous injection of placebo every day during 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Description: subcutaneous injection of anakinra every day during 16 weeks
Study: NCT02693184

Intervention type: OTHER
Intervention: Full length Block 2014 Food Frequency Questionnaire
Description: The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.

Intervention type: OTHER
Intervention: Revised Calcium, Vitamin D and Protein Screener
Description: The food list includes 29 food items and 5 supplements
Study: NCT01993394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypergravity
Description: 1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas mixture
Description: breathing air, 44.5%O2 or 100%O2